Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor
Cyxone (publ), a biotech company in autoimmune diseases, re-engages Professor Rikard Holmdahl as Scientific Advisor for the company’s projects in autoimmune diseases.
Rikard Holmdahl has long established experience and expert knowledge in immunology and autoimmune diseases. Professor Holmdahl is one of Sweden’s leading scientists in immunology who has contributed to very valuable insights into the mechanisms causing chronic inflammatory diseases such as multiple sclerosis and rheumatoid arthritis. He has during his career been acknowledged with several prestigious scientific prizes for his pioneering research.
Professor Holmdahl is a member of the Royal Swedish Academy of Sciences and has also been part of the Nobel Assembly between 2014 and 2021. Since 2008, Holmdahl has led a world-leading team of scientists in inflammatory diseases at Karolinska Institute (KI) and has been one of the leading scientists behind the discovery of Cyxone’s drug candidate rabeximod.
Professor Rikard Holmdahl comments: “I am looking forward to continuing following the exciting development of rabeximod and in the best possible way supporting Cyxone’s team in their efforts to bring this interesting drug candidate to the market. Rabeximod is a unique molecule developed by Swedish scientists based on the assumption it could block inflammation. Using preclinical models, we later understood that it was efficient for treatment of arthritis, and we also got some useful ideas of its function. On that basis a clinical trial was conducted which demonstrated a relevant therapeutic effect, but we also thought it could be further improved by changing the treatment protocol, which Cyxone now is exploring in a very interesting way.”
”It is an honor that Professor Holmdahl now re-engages in Cyxone’s Scientific Advisory Board and actively demonstrates his great interest to continue to support rabeximod in the development of a treatment which has the potential to fulfill unmet medical needs for patients with rheumatoid arthritis. Rikard Holmdahl has been a valuable part in establishing the rabeximod project from the start. He is very knowledgeable in the processes causing the diseases where we see opportunities to use rabeximod, and he also has a large established network in the scientific community which is extremely valuable to a company like Cyxone”, says Carl-Magnus Högerkorp, CEO of Cyxone.Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.comOpen Press release